Cargando…

Clinical impact of biologic therapy in the treatment of SLE

Detalles Bibliográficos
Autor principal:	Wallace, Daniel J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Meeting Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3890904/ http://dx.doi.org/10.1186/ar4223

Ejemplares similares

Clinical and immunological effects of anti-TNF therapy in systemic lupus erythematosus (SLE)
por: Aringer, M, et al.
Publicado: (2003)

The role of DNA in the pathogenesis of SLE
por: Pisetsky, DS
Publicado: (2001)

Genetic analysis of the pentraxin genes in SLE
por: Russell, AI, et al.
Publicado: (2001)

Vasculitis and Systemic Lupus Erythematous (SLE)
por: Cortis, Elisabetta, et al.
Publicado: (2015)

Signalling via T cell receptor (TCR) in patients with SLE
por: Cebecauer, M, et al.
Publicado: (2001)

High score on PREDICTS is associated with 10-fold increased odds for the progression of subclinical atherosclerosis in SLE
por: McMahon, M, et al.
Publicado: (2012)

T lymphocytes of patients with SLE lack Stat4
por: Aringer, M, et al.
Publicado: (2001)

SLE risk alleles and cell development and activation
por: Kim, SJ, et al.
Publicado: (2012)

SLE: insights from array-based proteomics
por: Wu, T, et al.
Publicado: (2012)

B cells at the adaptive-innate immune system interface in SLE
por: Anolik, JH, et al.
Publicado: (2012)

Neuropsychiatric events in SLE: determination of attribution and assessment of outcome
por: Hanly, JG
Publicado: (2012)

PROMISSE: progress in understanding pregnancy complications in patients with SLE
por: Salmon, JE
Publicado: (2012)

Regulatory natural autoantibodies suppress inflammation and SLE disease activity
por: Silverman, GJ, et al.
Publicado: (2012)

Mycophenolate mofetil prevents the development of a clinical relapse in SLE patients at risk: an open pilot study
por: Bijl, M, et al.
Publicado: (2002)

Nucleosome binding by serum amyloid P component from SLE patients
por: Heegaard, NHH, et al.
Publicado: (2001)

Elevated anti-serum amyloid P component (SAP) antibodies in SLE patients
por: Zandman-Goddard, G, et al.
Publicado: (2003)

Interplay of neutrophils and type I interferons in the development of end-organ damage in SLE
por: Kaplan, MJ
Publicado: (2012)

Autoantibodies to hnRNP-A2 in SLE: identification of disease-specific linear epitopes and correlation with disease activity and clinical features
por: Schett, G, et al.
Publicado: (2003)

Aggregation of MAVS antiviral protein suggests a mechanism for increased type I interferon production in SLE
por: Shao, Wen-Hai, et al.
Publicado: (2014)

Comparison of different immunoassays detecting anti-chromatin autoantibodies in systemic lupus erythematosus (SLE)
por: Roux-Lombard, P, et al.
Publicado: (2002)

Immuno-serological profile of Systemic Erythemic Lupus (SLE) patients with neuropsychiatric manifestations (NP)
por: Stojanovich, L, et al.
Publicado: (2001)

IRF5 expression profiling in SLE patients: new leads to a pathogenic signature?
por: Barnes, BJ, et al.
Publicado: (2012)

Sociodemographic characteristics of SLE patients in a large metropolitan area with a high Afro-Caribbean population
por: Cabas-Vargas, J, et al.
Publicado: (2012)

MicroRNA-3148 modulates differential gene expression of the SLE-associated TLR7 variant
por: Deng, Y, et al.
Publicado: (2012)

Characterization of RA33 (hnRNP-A2/B1)-autoreactive T cells in SLE-patients
por: Fritsch, R, et al.
Publicado: (2001)

Validating the expression of miRNAs in healthy controls and SLE patients and to predict possible gene targets
por: Chugha, Amandeep, et al.
Publicado: (2015)

Autoantibodies to the TNF-α translational regulators TIA-1 and TIAR occur frequently in sera of patients with SLE and scleroderma
por: Jimenez-Boj, E, et al.
Publicado: (2002)

The association of HLA-DR/DQ coding and QBP promoter allelic polymorphism with antiphospholipid antibody response in SLE
por: Logar, D, et al.
Publicado: (2002)

Effects of atacicept on disease activity in patients with moderate to severe systemic lupus erythematosus: APRIL-SLE randomized trial
por: Isenberg, David, et al.
Publicado: (2014)

Dominance of hydrophobic reading frames in complementarity determining region 3 of variable heavy chain genes from a patient with untreated SLE
por: Yazdani-Biuki, B, et al.
Publicado: (2001)

Skin-antigen specific antibodies are detected in UV irradiation and TLR7 agonist induced lupus-like disease in autoimmune prone NOD mice and in pediatric SLE
por: Ghoreishi, M, et al.
Publicado: (2012)

SLE patients and autoantibody-positive healthy individuals display unique cytokine profiles: shared features of inflammation as well as select features of immunosuppression in autoantibody-positive healthy individuals
por: Ritterhouse, LL, et al.
Publicado: (2012)

P03-014 - Biological therapy for autoinflammatory disorders
por: Rivas, S Bujan, et al.
Publicado: (2013)

Impact of carrier solution on biological insulin availability
por: Rusavý, Z, et al.
Publicado: (2000)

Production of IFN-α by Natural IFN-α Producing Cells (NIPC), induced by apoptotic cells and autoantibodies via FcγRII, could be a pivotal event in the etiopathogenesis of SLE
por: Rönnblom, LR, et al.
Publicado: (2002)

Patient perceptions and preferences of biologic therapies in SLE
por: Lim, S Sam, et al.
Publicado: (2019)

Biological therapies in monogenic autoinflammatory diseases: long-term efficacy and safety
por: Pelagatti, Maria A, et al.
Publicado: (2014)

Cluster analysis of longitudinal treatment patterns in patients newly diagnosed with systemic lupus erythematosus in the United States
por: Kan, Hong, et al.
Publicado: (2014)

Outcome measures in systemic lupus erythematosus: constructing a meaningful response index from existing clinical trial data
por: Forbess, Lindsy, et al.
Publicado: (2014)

Personalized cancer care through biology informed treatment decisions
por: Kuhn, Peter
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_5kujlakp2vpppa79mdbi6pbjmr